← Leaderboards
Roland Jurecic
University Of Miami School Of Medicine
$4,057,665
Attributed
$4,057,665
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $560.3K · FY2006–20$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$4,057,665 · 3
By mechanism
R01$3,718,578 · 2
R21$339,087 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Miami School Of Medicine
Same institution · by research overlap
- Huw S. Kruger Gray$1,102,729
- Beatriz Marina Avila Fontoura$11,923,585
- Mary Lou King$4,616,127
- Teresa A Zimmers$8,645,385
- Christine K Thomas$6,518,163
Others in their field
Top investigators on “Hematopoietic Stem Cells”
- Mary M Horowitz · Medical College Of Wisconsin$222,127,419
- Hans-Peter Kiem · Fred Hutchinson Cancer Center$80,540,126
- David T Scadden · Massachusetts General Hospital$40,987,034
- David A Williams · Indiana Univ-Purdue Univ At Indianapolis$36,503,708
- Irving Lerner Weissman · Stanford University$36,281,548
- Bruce R. Blazar · University Of Minnesota$33,175,355
Research focus
Hematopoietic Stem CellsProgenitorReportingHematopoiesisAffectAdjuvantDefectFrequenciesClinical ResearchChronicCancer PatientAttenuatedBacteremiaBacterial InfectionsEarly Embryonic StageCancer SurvivorAnticancer ResearchCancer TherapyAdverse OutcomeChemotherapyBreast Cancer ModelChemotherapy-Oncologic ProcedureBioassayAdverse Effects
Grant awards (11)
(PQ9) Characterization and prophylactic treatment of chemotherapy-induced long-term adverse sequelae$560,277
R01 · FY2020 · CA · contact PI
(PQ9) Characterization and prophylactic treatment of chemotherapy-induced long-term adverse sequelae$543,470
R01 · FY2019 · CA · contact PI
(PQ9) Characterization and prophylactic treatment of chemotherapy-induced long-term adverse sequelae$560,277
R01 · FY2018 · CA · contact PI
(PQ9) Characterization and prophylactic treatment of chemotherapy-induced long-term adverse sequelae$560,277
R01 · FY2017 · CA · contact PI
(PQ9) Characterization and prophylactic treatment of chemotherapy-induced long-term adverse sequelae$560,277
R01 · FY2016 · CA · contact PI
THE ROLE OF TR-KIT RECEPTOR IN STEM CELL MAINTENANCE AND DIFFERENTIATION$182,732
R21 · FY2007 · AG · contact PI
THE ROLE OF TR-KIT RECEPTOR IN STEM CELL MAINTENANCE AND DIFFERENTIATION$156,355
R21 · FY2006 · AG · contact PI
DEVELOPMENT OF HEMATOPOIETIC STEM CELLS$227,250
R01 · FY2004 · RR
DEVELOPMENT OF HEMATOPOIETIC STEM CELLS$227,250
R01 · FY2003 · RR
DEVELOPMENT OF HEMATOPOIETIC STEM CELLS$227,250
R01 · FY2002 · RR
DEVELOPMENT OF HEMATOPOIETIC STEM CELLS$252,250
R01 · FY2001 · RR